Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Y-3 (Loberamisal) in Hepatic Insufficiency
NCT07055412Phase 1Not yet recruiting
- Sponsor
- NeuroDawn
- Start
- Jul 2025
- Primary completion
- Oct 2025
01
Overview
Phase 1, open-label trial of loberamisal in ischemic stroke and major depressive disorder (MDD) (3 arms), sponsored by NeuroDawn. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last quantifiable concentration and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
loberamisal
03
Conditions
ischemic strokemajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07055412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055412.